Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onglyza

- PMLiVE

FDA refuses to back Gilead’s two HIV drugs

Agency questions quality of testing procedures for elvitegravir and cobicistat

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

- PMLiVE

Lilly expects to submit five drugs for US approval in 2013

Hopes FDA submissions will help offset patent losses for Zyprexa and Cymbalta

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

Boehringer: Move towards trial transparency is “irreversible”

Pharma company plans to publish all scientific data

- PMLiVE

Boehringer to restructure in Southern Europe

Closes chemical plant in France as part of plans to “adapt” business structure

- PMLiVE

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma company

- PMLiVE

Novo Nordisk launches new US insulin campaign

US IndyCar driver, diabetic and FlexPen user Charlie Kimball fronts activities

- PMLiVE

Infographic: Type 2 diabetes in Brazil

Key facts about the chronic condition's impact in the emerging market

- PMLiVE

Brazil: Patient access and education in type 2 diabetes

As the prevalence of diabetes increases in Brazil, the healthcare system needs to respond 

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links